Malaga

• A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma Recruiting
  2025-522307-14-00 2 2026-01-19 Melanoma
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN ) Recruiting
  2025-522631-34-00 5 2026-01-14 Osteoarthritis
• A study to learn more about how well finerenone works, how safe it is, and how it moves into, through, and out of the body compared to place … Recruiting
  2024-519829-38-00 5 2026-01-09 Heart failure due to systemic left ventricular systolic dysfunction
• A Study to Learn About Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants Recruiting
  2022-503070-36-00 5 2025-12-23 Group B streptococcus (GBS) disease
• Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD) Recruiting
  2025-522680-14-00 2 2025-12-23 Chronic Graft-versus-Host Disease
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting
  2025-521003-52-00 9 2025-12-19 HER2 Expressing Advanced Breast Cancer
• Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis Recruiting
  2024-518288-37-00 3 2025-12-18 Lupus Nephritis
• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants with Advanced Solid Tumors Recruiting
  2025-522203-23-00 7 2025-12-18 Advanced Solid Tumors
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol … Recruiting
  2025-522004-24-00 11 2025-12-11 iron deficient
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re … Recruiting
  2024-515201-26-00 4 2025-12-09 Small cell lung cancer (SCLC)
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat … Recruiting
  2024-519913-76-00 4 2025-12-09 PDL1-negative metastatic triple-negative breast cancer
• A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors Recruiting
  2025-522274-37-00 9 2025-12-03 Neoplasms
• A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATI … Recruiting
  2023-508874-27-00 5 2025-12-02 Heart condition
• A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting
  2024-512577-27-00 5 2025-12-02 Chronic kidney disease in paediatric patients
• Phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial ca … Recruiting
  2024-512021-81-00 4 2025-12-01 MMRd/MSI-H stage II-III endometrial cancer
• A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-thr … Recruiting
  2025-521697-34-00 5 2025-12-01 Peanut allergy
• A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 … Recruiting
  2025-521391-58-00 4 2025-11-28 Asthma
• A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck … Recruiting
  2024-517091-38-00 3 2025-11-25 Head and neck squamous cell carcinoma
• A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus … Recruiting
  2024-519590-19-00 4 2025-11-25 PD-L1 positive advanced colorectal cancer

Showing 241–264 of 1,048 trials